« Back
Home /
Suvorexant

Suvorexant

Item no.	DCC-DC5017-10mM
Manufacturer	DCChemicals
CASRN	1030377-33-3
Amount	10 mM x 1 ml in DMSO
Quantity options	100 mg 10 mM x 1 ml in DMSO 1 g 250 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Applications	IV
Specific against	other
Smiles	ClC1C([H])=C([H])C2=C(C=1[H])N=C(N1C([H])([H])C([H])([H])N(C(C3C([H])=C(C([H])([H])[H])C([H])=C([H])C=3N3N=C([H])C([H])=N3)=O)[C@]([H])(C([H])([H])[H])C([H])([H])C1([H])[H])O2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Manufacturer - Applications	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.Suvorexant is an analytical reference standard categorized as a diazepane sedative.Formulations containing suvorexant show abuse potential similar to zolpidem in recreational polydrug users with a history of sedative and psychedelic drug use.2 Suvorexant is regulated as a Schedule IV compound in the United States. This product is intended for use in analytical forensic applications.
Molecular Weight	450, 9207

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mM x 1 ml in DMSO

available

Delivery expected until 11/13/2025

Compare

Add to wishlist

Get an offer

Request delivery time